$EXEL
EXELIXIS, INC.

2022 Q2 Form 10-Q Financial Statement

#000093976722000058 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q4 2021 Q2
Revenue $356.0M $328.4M $270.2M
YoY Change 31.73% 42.12% 19.09%
Cost Of Revenue $13.20M $11.87M $13.20M
YoY Change 0.04% 36.09% 42.08%
Gross Profit $342.8M $316.5M $257.0M
YoY Change 33.36% 98.01% 39.24%
Gross Profit Margin 96.29% 96.38% 95.12%
Selling, General & Admin $102.9M $101.6M $102.4M
YoY Change 0.5% 15.16% 62.62%
% of Gross Profit 30.01% 32.08% 39.82%
Research & Development $156.7M $163.4M $159.3M
YoY Change -1.64% -7.58% 56.35%
% of Gross Profit 45.71% 51.61% 61.97%
Depreciation & Amortization $4.490M $1.931M $3.227M
YoY Change 39.14% -19.54% 48.37%
% of Gross Profit 1.31% 0.61% 1.26%
Operating Expenses $259.5M $264.9M $261.6M
YoY Change -0.8% -0.01% 58.75%
Operating Profit $83.24M $51.62M -$4.607M
YoY Change -1906.88% -221.23% -108.72%
Interest Expense $4.757M $1.441M $1.891M
YoY Change 151.56% -58.83% -63.63%
% of Operating Profit 5.71% 2.79%
Other Income/Expense, Net $164.0K -$19.00K -$90.00K
YoY Change -282.22% -103.36% -1600.0%
Pretax Income $88.51M $118.0M -$2.015M
YoY Change -4492.46% -410.41% -103.36%
Income Tax $16.66M $15.06M -$3.616M
% Of Pretax Income 18.82% 12.76%
Net Earnings $68.57M $38.20M $1.601M
YoY Change 4183.14% -219.24% -96.71%
Net Earnings / Revenue 19.26% 11.63% 0.59%
Basic Earnings Per Share $0.21 $0.12 $0.01
Diluted Earnings Per Share $0.21 $0.12 $0.00
COMMON SHARES
Basic Shares Outstanding 319.6M shares 315.4M shares 312.5M shares
Diluted Shares Outstanding 323.3M shares 322.0M shares 321.3M shares

Balance Sheet

Concept 2022 Q2 2021 Q4 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.535B $1.467B $1.347B
YoY Change 13.98% 21.6% 11.02%
Cash & Equivalents $723.3M $647.2M $370.2M
Short-Term Investments $907.9M $819.9M $854.2M
Other Short-Term Assets $48.28M $57.53M $40.13M
YoY Change 20.31% 0.93% 33.32%
Inventory $28.47M $27.49M $24.76M
Prepaid Expenses
Receivables $235.4M $282.7M $181.5M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.843B $1.835B $1.434B
YoY Change 28.48% 30.33% 26.16%
LONG-TERM ASSETS
Property, Plant & Equipment $106.2M $104.0M $78.45M
YoY Change 35.33% 84.5% 61.8%
Goodwill $63.68M $63.68M $63.68M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $463.9M $371.1M $298.8M
YoY Change 55.26% 11.68% -8.21%
Other Assets $139.0M $131.0M $124.7M
YoY Change 11.47% 88.74% 117.55%
Total Long-Term Assets $811.4M $781.5M $756.3M
YoY Change 7.29% 11.13% -7.63%
TOTAL ASSETS
Total Short-Term Assets $1.843B $1.835B $1.434B
Total Long-Term Assets $811.4M $781.5M $756.3M
Total Assets $2.654B $2.616B $2.191B
YoY Change 21.16% 23.93% 12.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.29M $24.26M $13.82M
YoY Change 25.06% -49.39% -9.79%
Accrued Expenses $168.2M $226.3M $139.8M
YoY Change 20.28% 95.23% 66.86%
Deferred Revenue $7.349M $7.814M $9.207M
YoY Change -20.18% 501.08% 608.23%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $289.1M $337.6M $213.3M
YoY Change 35.5% 67.67% 51.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.52M $8.023M $3.421M
YoY Change 265.89% 1012.76% -37.33%
Total Long-Term Liabilities $12.52M $8.023M $3.421M
YoY Change 265.89% 1012.76% -37.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $289.1M $337.6M $213.3M
Total Long-Term Liabilities $12.52M $8.023M $3.421M
Total Liabilities $360.3M $405.6M $279.4M
YoY Change 28.96% 56.6% 34.34%
SHAREHOLDERS EQUITY
Retained Earnings -$147.9M -$216.5M -$446.0M
YoY Change -66.83% -54.51% -12.68%
Common Stock $320.0K $319.0K $313.0K
YoY Change 2.24% 3.24% 2.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.294B $2.211B $1.911B
YoY Change
Total Liabilities & Shareholders Equity $2.654B $2.616B $2.191B
YoY Change 21.16% 23.93% 12.01%

Cashflow Statement

Concept 2022 Q2 2021 Q4 2021 Q2
OPERATING ACTIVITIES
Net Income $68.57M $38.20M $1.601M
YoY Change 4183.14% -219.24% -96.71%
Depreciation, Depletion And Amortization $4.490M $1.931M $3.227M
YoY Change 39.14% -19.54% 48.37%
Cash From Operating Activities $147.7M $96.45M $39.54M
YoY Change 273.56% 189.65% -29.48%
INVESTING ACTIVITIES
Capital Expenditures $5.609M -$15.96M $13.56M
YoY Change -58.63% 12.39% 357.85%
Acquisitions
YoY Change
Other Investing Activities -$122.8M $2.905M -$50.62M
YoY Change 142.59% -119.11% -163.12%
Cash From Investing Activities -$74.54M -$13.06M $62.26M
YoY Change -219.73% -55.75% 90.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $205.0K -17.99M -$2.650M
YoY Change -107.74% -3.78% -223.54%
NET CHANGE
Cash From Operating Activities $147.7M 96.45M $39.54M
Cash From Investing Activities -$74.54M -13.06M $62.26M
Cash From Financing Activities $205.0K -17.99M -$2.650M
Net Change In Cash $73.39M 65.40M $99.15M
YoY Change -25.99% -538.95% 9.15%
FREE CASH FLOW
Cash From Operating Activities $147.7M $96.45M $39.54M
Capital Expenditures $5.609M -$15.96M $13.56M
Free Cash Flow $142.1M $112.4M $25.99M
YoY Change 446.85% 136.66% -51.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 dei Document Type
DocumentType
10-Q
CY2022Q2 dei Amendment Flag
AmendmentFlag
false
CY2022Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q2 dei Entity Central Index Key
EntityCentralIndexKey
0000939767
CY2022Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q2 dei Document Period End Date
DocumentPeriodEndDate
2022-04-01
CY2022Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 dei Entity File Number
EntityFileNumber
000-30235
CY2022Q2 dei Entity Registrant Name
EntityRegistrantName
EXELIXIS, INC.
CY2022Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3257395
CY2022Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
1851 Harbor Bay Parkway
CY2022Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Alameda,
CY2022Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94502
CY2022Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q2 dei City Area Code
CityAreaCode
650
CY2022Q2 dei Local Phone Number
LocalPhoneNumber
837-7000
CY2022Q2 dei Security12b Title
Security12bTitle
Common Stock $.001 Par Value per Share
CY2022Q2 dei Trading Symbol
TradingSymbol
EXEL
CY2022Q2 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q2 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
320740721 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
723269000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
647169000 USD
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
847060000 USD
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
819905000 USD
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
190614000 USD
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
282650000 USD
CY2022Q2 us-gaap Inventory Net
InventoryNet
28467000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
27493000 USD
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
53333000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
57530000 USD
CY2022Q2 us-gaap Assets Current
AssetsCurrent
1842743000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1834747000 USD
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
404535000 USD
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
371112000 USD
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106169000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104031000 USD
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
98001000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
111663000 USD
CY2022Q2 us-gaap Goodwill
Goodwill
63684000 USD
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6665000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
63684000 USD
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
138986000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131002000 USD
CY2022Q2 us-gaap Assets
Assets
2654118000 USD
CY2021Q4 us-gaap Assets
Assets
2616239000 USD
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
17285000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
24258000 USD
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
42768000 USD
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
61969000 USD
CY2022Q2 exel Accrued Clinical Liabilities Current
AccruedClinicalLiabilitiesCurrent
82885000 USD
CY2021Q4 exel Accrued Clinical Liabilities Current
AccruedClinicalLiabilitiesCurrent
77544000 USD
CY2022Q2 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
49997000 USD
CY2021Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
33700000 USD
CY2022Q2 exel Accrued Collaboration Liability Current
AccruedCollaborationLiabilityCurrent
32492000 USD
CY2021Q4 exel Accrued Collaboration Liability Current
AccruedCollaborationLiabilityCurrent
86753000 USD
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
63652000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53366000 USD
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
289079000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
337590000 USD
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8035000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8739000 USD
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50636000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51272000 USD
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12517000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8023000 USD
CY2022Q2 us-gaap Liabilities
Liabilities
360267000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
405624000 USD
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
320268000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
320268000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
318842000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
318842000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
320000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
319000 USD
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2448130000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2427561000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-758000 USD
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147934000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216507000 USD
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2293851000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2210615000 USD
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2654118000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2616239000 USD
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
355980000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
270230000 USD
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13203000 USD
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13198000 USD
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
156671000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159288000 USD
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102863000 USD
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102351000 USD
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
272737000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
274837000 USD
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
83243000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4607000 USD
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
1822000 USD
CY2021Q2 us-gaap Interest Income Other
InterestIncomeOther
2682000 USD
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
164000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000 USD
CY2022Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
85229000 USD
CY2021Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2015000 USD
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16656000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3616000 USD
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1601000 USD
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5907000 USD
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
319582000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
312473000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
323289000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
323289000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
321287000 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1601000 USD
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1656000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
499000 USD
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5907000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1736000 USD
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
62666000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2210615000 USD
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 USD
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5513000 USD
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4960000 USD
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20017000 USD
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2293851000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1879113000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1601000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1736000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4202000 USD
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6646000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34653000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1911187000 USD
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1601000 USD
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4490000 USD
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3227000 USD
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
19759000 USD
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
34653000 USD
CY2022Q2 exel Noncash Lease Expense
NoncashLeaseExpense
1385000 USD
CY2021Q2 exel Noncash Lease Expense
NoncashLeaseExpense
1221000 USD
CY2022Q2 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-15318000 USD
CY2021Q2 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
3388000 USD
CY2022Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1580000 USD
CY2021Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6578000 USD
CY2022Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-91793000 USD
CY2021Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17690000 USD
CY2022Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3520000 USD
CY2021Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2090000 USD
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3605000 USD
CY2021Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1872000 USD
CY2022Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1169000 USD
CY2021Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
13422000 USD
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-54261000 USD
CY2021Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1005000 USD
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7376000 USD
CY2021Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-867000 USD
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
147719000 USD
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
39544000 USD
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5609000 USD
CY2021Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13557000 USD
CY2022Q2 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
336545000 USD
CY2021Q2 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
331612000 USD
CY2022Q2 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
267615000 USD
CY2021Q2 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
407424000 USD
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74539000 USD
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
62255000 USD
CY2022Q2 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4891000 USD
CY2021Q2 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2791000 USD
CY2022Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4686000 USD
CY2022Q2 us-gaap Fiscal Period
FiscalPeriod
<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2022, which is a 52-week fiscal year, will end on December 30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December 31, 2021. For convenience, references in this report as of and for the three months ended April 1, 2022 and April 2, 2021, and as of and for the fiscal year ending December 30, 2022 are indicated as being as of and for the three months ended March 31, 2022 and March 31, 2021, and the year ending December 31, 2022, respectively.
CY2022Q2 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5441000 USD
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205000 USD
CY2021Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2650000 USD
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73385000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
99149000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663891000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
320772000 USD
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
737276000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
419921000 USD
CY2022Q2 exel Number Of Countries With Drug Approval Excluding The Us
NumberOfCountriesWithDrugApprovalExcludingTheUS
61 country
CY2022Q2 us-gaap Use Of Estimates
UseOfEstimates
The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
CY2022Q2 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders’ equity.
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
355980000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
270230000 USD
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
355980000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
270230000 USD
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
48325000 USD
CY2022Q2 exel Valuation Allowances And Reserves Additions For Sales In Current Period
ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
137441000 USD
CY2022Q2 exel Valuation Allowances And Reserves Additions For Sales In Prior Period
ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
498000 USD
CY2022Q2 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
117872000 USD
CY2022Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
68392000 USD
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3235000 USD
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1665000 USD
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7349000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7814000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
934000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1730000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1533668000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1855704000 USD
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8035000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8739000 USD
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
15384000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16553000 USD
CY2022Q2 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
2400000 USD
CY2021Q2 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
2500000 USD
CY2022Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
31700000 USD
CY2021Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
27800000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
934000 USD
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
723269000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
647169000 USD
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
14007000 USD
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16722000 USD
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
737276000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663891000 USD
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1694472000 USD
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
100000 USD
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8459000 USD
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1686113000 USD
CY2022Q2 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1997230000 USD
CY2022Q2 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
100000 USD
CY2022Q2 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8459000 USD
CY2022Q2 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
1988871000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1534464000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1730000 USD
CY2021Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
1854908000 USD
CY2022Q2 us-gaap Interest Receivable
InterestReceivable
2600000 USD
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
2900000 USD
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
698886000 USD
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
8459000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
454780000 USD
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1730000 USD
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
197 investment
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
133 investment
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1290576000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1168256000 USD
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
395537000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
365412000 USD
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1686113000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1533668000 USD
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
10858000 USD
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
8867000 USD
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
27778000 USD
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
27717000 USD
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
14653000 USD
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12927000 USD
CY2022Q2 us-gaap Inventory Gross
InventoryGross
53289000 USD
CY2021Q4 us-gaap Inventory Gross
InventoryGross
49511000 USD
CY2022Q2 us-gaap Inventory Gross
InventoryGross
53289000 USD
CY2021Q4 us-gaap Inventory Gross
InventoryGross
49511000 USD
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19759000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34653000 USD
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19759000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34653000 USD
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4152901 shares
CY2022Q2 exel Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
1 shares
CY2022Q2 exel Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Other Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
1.5 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
233476 shares
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.02
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.51
CY2022Q1 exel Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Maximum Potential To Vest
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
1.75
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
24800000 USD
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1601000 USD
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
319582000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
312473000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3707000 shares
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
8814000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
323289000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
321287000 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00

Files In Submission

Name View Source Status
0000939767-22-000058-index-headers.html Edgar Link pending
0000939767-22-000058-index.html Edgar Link pending
0000939767-22-000058.txt Edgar Link pending
0000939767-22-000058-xbrl.zip Edgar Link pending
exel-20220401.htm Edgar Link pending
exel-20220401.xsd Edgar Link pending
exel-20220401_cal.xml Edgar Link unprocessable
exel-20220401_def.xml Edgar Link unprocessable
exel-20220401_g1.jpg Edgar Link pending
exel-20220401_htm.xml Edgar Link completed
exel-20220401_lab.xml Edgar Link unprocessable
exel-20220401_pre.xml Edgar Link unprocessable
exel20210331exhibit10110q.htm Edgar Link pending
exel20210331exhibit10210q.htm Edgar Link pending
exel20210331exhibit31210q.htm Edgar Link pending
exel20220331exhibit31110q.htm Edgar Link pending
exel20220331exhibit32110q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
image_1.jpg Edgar Link pending
image_2.jpg Edgar Link pending
image_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending